Circulatory assist techniques in cardiogenic shock: metabolic aspects.
Assisted circulation in severe cardiogenic shock was evaluated using a reservoir and a single pump without an oxygenator in 88 dogs. Study groups included: no treatment, substrates only (cysteine, ribose), nitroprusside, left ventricular (LV) + right atrial (RA) bypass + substrates, LV + RA bypass, left atrial (LA) + RA bypass, LA bypass, LV bypass, LV + RA + fluosol. Metabolic studies of O2 consumption, acid and alkaline phosphatase, lactate, creatine phosphokinase (CPK), myocardial depressant factor (MDF), and tissue adenosine triphosphate (ATP) were done in the course of 4-hour treatment periods followed by 2-hour observation periods. Best survival at 4-hour and 6-hour levels were achieved in LV + RA bypass. Cysteine and ribose reduced survival when added to the pump supported (LV + RA bypass) group. Cysteine/ribose improved survival over the no treatment group. O2 consumption increased significantly in the groups with best survival but remained unchanged from control or shock levels when cysteine/ribose were added. Unusually high levels of CPK, acid and alkaline phosphatase, and MDF occurred in both groups receiving cysteine/ribose, indicating significant organ damage correlating with poor survival. Lactate levels were less predictive. Heart tissue ATP levels were higher in groups with good survival. Liver ATP levels were lower in high survival groups. Lung ATP did not differ between groups.
Surgical Service, Department of Veterans Affairs, Washington, D.C. 20420.
A A
AA
Lefemine
J
J
Dunbar
D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001243:Assisted Circulation; D001802:Blood Substitutes / Q000008:administration & dosage; D003402:Creatine Kinase / Q000378:metabolism; D003545:Cysteine / Q000008:administration & dosage; D004285:Dogs; D005466:Fluorocarbons / Q000008:administration & dosage; D009599:Nitroprusside / Q000008:administration & dosage; D010101:Oxygen Consumption; D012266:Ribose / Q000008:administration & dosage; D012770:Shock, Cardiogenic / Q000378:metabolism* / Q000628:therapy*
D001802:Blood Substitutes; D005466:Fluorocarbons; D009599:Nitroprusside; D012266:Ribose; C050455:fluosol; D003402:Creatine Kinase; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D003545:Cysteine